

Dr. LEE. I think we can consult with Justice on this, but I think we could certainly provide a draft of what would be in such an agreement.

We plan to have the next meeting on the 27th of March with Justice to work on the research and education components of such an agreement.

Mr. HOLIFIELD. If you could give us a draft of the principles that you are going to work toward, and that is in general agreement, on a gentleman's agreement basis. I wouldn't ask you for a finished document. But this is our intention, to achieve complete line coordination on the basis of an agreement between the two agencies which will provide no break in function, no break in authority, no confusion, but a contingent, efficient coordination of the backup people with the enforcement people. This would be helpful to me.

Dr. LEE. Yes, sir; we will do that.

Mr. HOLIFIELD. And I think it would be helpful to the members. (The draft statement referred to follows:)

DRAFT STATEMENT OF IMMEDIATE AND INTERIM SERVICE TO BE PROVIDED BY FOOD AND DRUG ADMINISTRATION LABORATORIES TO THE PROPOSED BUREAU OF NARCOTICS AND DANGEROUS DRUGS IN THE DEPARTMENT OF JUSTICE

FDA LABORATORY SUPPORT—IMMEDIATE AND INTERIM SERVICE

Traditionally, since the formation of BDAC and passage of DACA, drug evidence collected by BDAC agents has been examined in the 17 district laboratories of the Food and Drug Administration and the laboratories of the Bureau of Science, Washington, D.C. Upon the merger of BDAC with the Bureau of Narcotics into the Department of Justice, it is recommended that evidence suspected to be a dangerous drug controlled under DACA and collected by agents of the Bureau of Narcotics and Dangerous Drugs should continue to be examined by the FDA laboratories. This arrangement will continue until the long-range planning studies can be made toward arranging for combined laboratory service to handle this activity for the new Bureau and we would expect to renegotiate as the situation arises.

1. *Handling of DACA evidence by FDA district laboratories*

A. All 17 FDA district laboratories will continue to examine DACA drug evidence collected by BNDD agents and submitted on Form FD-1964: Report of Drugs Collected Purchased or Seized.

B. Outstanding instructions to the district laboratories regarding the handling of DACA evidence presently in effect will continue in effect after the merger date of April 8, 1968. This includes those instructions in the Laboratory Operations Manual, section 2.7, entitled, "Bureau of Drug Abuse Control Samples," and other memoranda of understanding on the handling of DACA evidence which have been issued jointly by the Director of the Bureau of Drug Abuse Control and the Assistant Commissioner for Field Coordination.

C. The district laboratories will continue to supply technical assistance to the Bureau of Narcotics and Dangerous Drugs on requests, for example, examination of evidence after regular working hours and the assistance of a chemist to help agents catalog evidence after a raid on an illegal laboratory.

D. The district laboratories will make available those chemists who have or will have examined DACA evidence when necessary as expert witnesses for court cases.

2. *Handling of DACA evidence by the Bureau of Science Laboratories*

A. The Division of Pharmaceutical Chemistry's microanalytical group will continue to do ballistics examination of drugs submitted by BNDD agents. The new Bureau will continue to submit authentic drug samples for the ballistics library.

B. All drug evidence received from the program of assistance to State, local, and municipal law enforcement agencies will be examined by these laboratories.

C. The Division of Pharmaceutical Chemistry Laboratory personnel will handle